

Long-term clinical outcomes of mechanical versus bioprosthetic aortic valve replacement in older patients

Sung-Han Yoon¹, MD; Jung-Min Ahn¹, MD; Jihyun Song², PhD; Young-Hak Kim¹, MD; Cheol Whan Lee¹, MD; Jong-Young Lee¹, MD; Soo-Jin Kang¹, MD; Duk-Woo Park¹, MD; Seung-Whan Lee¹, MD; Joon Bum Kim³, MD; Sung-Ho Jung³, MD; Cheol Hyun Chung³, MD; Suk Jung Choo³, MD; Seong-Wook Park¹, MD; Jae Won Lee³, MD; Seung-Jung Park^{1*}, MD

1. Division of Cardiology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea; 2. Department of Statistics, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea 3. Department of Thoracic and Cardiovascular Surgery, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea

Sung-Han Yoon and Jung-Min Ahn contributed equally to this article.

KEYWORDS

- aortic valve replacement
- bioprosthetic valve
- mechanical valve

Abstract

Aims: To compare the long-term outcomes of mechanical valves as opposed to bioprosthetic valves in order to inform valve selection.

Methods and results: From January 1996 to December 2010, 561 patients aged 60 to 75 years undergoing AVR for the first time were evaluated (mechanical valve: N=251; bioprosthetic valve: N=310). The primary outcome was all-cause death, and secondary outcomes were reoperation, bleeding events, thromboembolism, endocarditis and major adverse prosthesis-related events (MAPE). MAPE were the composite of reoperation, bleeding, thromboembolism and endocarditis. Long-term outcomes were compared with the use of propensity scores to adjust for selection bias. After risk adjustment, both groups of patients showed a similar risk of death at 10 years (hazard ratio [HR] 1.25, 95% confidence interval [CI]: 0.85-1.85, p=0.26), reoperation (HR 2.94, 95% CI: 0.79-11.11, p=0.11) and thromboembolism (HR 0.38, 95% CI: 0.10-1.40, p=0.15). Compared with the patients given mechanical valves, those who received bioprosthetic valves were at a higher risk of endocarditis (HR 7.65, 95% CI: 1.74-33.52, p=0.007), but were however at a lower risk of bleeding (HR 0.25, 95% CI: 0.12-0.52, p<0.0001) and MAPE (HR 0.61, 95% CI: 0.39-0.96, p<0.033).

Conclusions: Compared with mechanical AVR, bioprosthetic AVR showed a similar long-term survival rate and favourable MAPE event rate.

*Corresponding author: Department of Cardiology, Asan Medical Center, University of Ulsan College of Medicine, 388-1 Poongap-dong, Songpa-gu, Seoul 138-736, South Korea. E-mail: sjpark@amc.seoul.kr

54 Abbreviations

55	AF	atrial fibrillation
56	AVR	aortic valve replacement
57	CABG	coronary artery bypass graft
58	CI	confidence interval
59	HR	hazard ratio
60	MAPE	major adverse prosthesis-related events
61	MI	myocardial infarction
62	NYHA	New York Heart Association
63	TAVR	transcatheter aortic valve replacement

65 Introduction

66 The current American Heart Association guidelines recommend
67 mechanical valves for aortic valve replacement (AVR) in patients
68 younger than 60 years, and bioprosthetic valves in patients older
69 than 70 years. Either a bioprosthetic or a mechanical valve is recom-
70 mended between 60 and 70 years¹. This grey zone reflects the
71 current trend towards increasing use of bioprostheses in progres-
72 sively younger patients², and also the complexities and trade-offs
73 of selecting an aortic valve prosthesis in older patients. Patients
74 with mechanical valves require lifelong anticoagulation, and risk
75 of bleeding events increases with advancing age. In contrast, risk
76 of reoperation in patients with bioprosthetic valves increases with
77 time and decreases with advancing age.

78 Two historic randomised clinical trials compared outcomes after
79 valve replacement with first-generation bioprosthetic and mechani-
80 cal valves^{3,4}. Although these trials are notable for their prospective,
81 randomised design, their major limitations are that comparisons
82 were made between first-generation valves, and most of the study
83 population in these trials was under 60 years of age. Furthermore,
84 recent innovation in transcatheter aortic valve replacement (TAVR)
85 is applicable to replace deteriorated biological prostheses, which
86 may affect the strategy in case of reoperation for octogenarians and
87 their late survival^{5,6}. To address the limitations of the earlier ran-
88 domised trials, a new randomised trial demonstrated the similar sur-
89 vival rate between bioprosthetic and mechanical valves but higher
90 incidence of bleeding events in mechanical valves and more fre-
91 quent reoperation in bioprosthetic valves⁷. Recently, large registry
92 data gave support to this with a similar result^{2,8}. However, it is not
93 clear whether this finding is applicable to other populations, includ-
94 ing an Asian population. Thus, we conducted a long-term observa-
95 tional study to compare outcomes of mechanical and bioprosthetic
96 valve replacement for patients aged more than 60 years in an Asian
97 population.

99 Methods

100 STUDY DESIGN

101 Patients who underwent valve surgery at our institution were pro-
102 spectively registered using a standard case-reporting form. Case
103 report forms, including patient demographics, clinical presenta-
104 tion, echocardiographic data, and procedural data were stored in an
105 electronic database. Clinical follow-up data of study patients were
106 prospectively collected via clinical visits or telephone, and entered

into the database at one month and six months after operation, and
subsequently on an annual basis. From January 1996 to December
2010, a total of 773 patients undergoing AVR with a mechanical
or bioprosthetic valve were consecutively enrolled in the present
study. The criteria for exclusion from the study were defined as
patients undergoing urgent surgery, or non-coronary artery bypass
graft cardiac surgical procedures, those with a prior history of any
valve replacement and who had received AVR for infective endo-
carditis (**Figure 1A**). All patients provided informed consent, and
the study was approved by the institutional review board.

CHOICE OF PROSTHESIS AND SURGICAL PROCEDURES

The selection of a mechanical or a bioprosthetic valve was made
following a detailed preoperative discussion among the surgeon,
the patient, and family members. The pros and cons of mechani-
cal or bioprosthetic valves were described, including the need
for anticoagulation after mechanical valve replacement or the
possible need for reoperation after bioprosthetic valve replace-
ment. The decision on mechanical or bioprosthetic selection
was left entirely to the individual patient and his/her carers. The
operation was conducted in the standard manner. Briefly, all
patients underwent AVR through a median sternotomy. A stand-
ard cannulation was performed in the routine fashion. After hav-
ing clamped the aorta and arrested the heart with antegrade/
retrograde cold blood, or cold crystalloid cardioplegia added to
topical cooling, the ascending aorta was opened and the valve
was replaced, either by a bioprosthetic or a mechanical valve
fixed to the aortic annulus.

ANTICOAGULATION

During the postoperative period, anticoagulated patients initially
received unfractionated heparin until the international normalised
ratio (INR) was within therapeutic range. Patients with mechani-
cal prostheses were anticoagulated with warfarin according to our
protocol to a target of INR 2.5 (range, 2.0 to 3.0). In patients who
underwent bioprosthetic valve replacement, warfarin anticoagu-
lation was used at the discretion of the surgeon for a period of
three months after the operation. Warfarin was subsequently dis-
continued if sinus rhythm was maintained and no other indication
for anticoagulation was present. Non-anticoagulated patients with
bioprosthetic valves were kept on 100 mg of aspirin daily unless
contraindicated.

OUTCOMES

The primary endpoint was the rate of death from any cause over
the duration of follow-up. Secondary endpoints were aortic valve
reoperation, bleeding events, thromboembolism and endocarditis.
Major adverse prosthesis-related events (MAPE) were the com-
posite of reoperation, bleeding events, thromboembolism and
endocarditis. These complications were defined according to the
guidelines for reporting mortality and morbidity after cardiac valve
intervention⁹. Briefly, a bleeding event is any episode of major
internal or external bleeding that causes death, hospitalisation, or

permanent injury, or necessitates transfusion. Thrombosis is any thrombus not caused by infection attached to or near an operated valve that occludes part of the blood flow path, interferes with valve function, or is sufficiently large to warrant treatment. Embolism is any embolic event that occurs in the absence of infection after the immediate period.

STATISTICAL ANALYSIS

Continuous variables are presented as the mean±standard deviation, and they were compared using the Student's t-test. Categorical variables are presented as counts or percentages, and they were compared using the chi-square test. A log-rank test was used to compare mortality and event rates between mechanical and bioprosthetic valves. A nonparametric Kaplan-Meier estimate was used to estimate the survival curve. To adjust for the difference in baseline characteristics between mechanical and bioprosthetic valves, the propensity score was estimated using the twang package in the R version 3.0.1 based on age, gender, body surface area, diabetes mellitus, hypertension, smoking status, previous myocardial infarction, previous stroke, New York Heart Association functional state, atrial fibrillation, chronic renal failure, left ventricular ejection fraction, and coronary artery bypass grafting. The propensity score matching was performed by matching between mechanical and bioprosthetic valve groups on the logit of the propensity score using a calliper of 0.2 SD of the logit of the propensity score¹⁰. Patients were censored at the time of their last follow-up visit or at the time of death if the outcome of interest had not occurred, and censoring was assumed to be independent of predictors and outcomes. Unadjusted hazard ratios and adjusted hazard ratios were derived from a Cox proportional hazards model with propensity

score matching. Statistical significance was defined as p-value <0.05. Data were analysed using SPSS Statistics version 21.0 (IBM Corp., Armonk, NY, USA) and R version 3.0.1 (the R Foundation for Statistical Computing, Vienna, Austria).

Results

PATIENT CHARACTERISTICS

A total of 561 patients (mechanical valve, N=251; bioprosthetic valve, N=310) were analysed in this study, and 531 patients (95.4%) completed follow-up. Patient age was 67.5±4.5 years (range, 60 to 75 years) at the time of surgery (**Table 1**). There were 319 (56.9%) male and 242 (43.1%) female patients. A total of 159 (28.3%) patients were in New York Heart Association (NYHA) functional Class III or IV. The total follow-up for the entire cohort was 3,167 patient-years, with a mean duration of 5.6 years (interquartile range: 2.2 to 8.3 years; maximum 15.6 years). The distribution of mechanical and bioprosthetic valves was constant across the age range (**Figure 1B**). Compared with patients who received mechanical valves, those who received bioprosthetic valves had lower body surface area and ejection fraction, but a similar age and prevalence of most other comorbidities. It was noted that patients with bioprosthetic valves were more likely to undergo concomitant coronary artery bypass graft surgery (28.1% versus 21.1%) but the difference did not reach statistical significance. The dominant underlying lesion was either isolated aortic stenosis (252 patients; 44.9%) or mixed aortic stenosis and regurgitation (182 patients; 32.4%). Intraoperative characteristics were similar for patients with bioprosthetic versus mechanical valves, with a similar mean time on cardiopulmonary bypass and aorta cross clamp time (**Table 2**).

Table 1. Baseline characteristics of the study population.

Variables	Overall				Propensity score-matched			
	Mechanical (N=251)	Bioprosthetic (N=310)	p-value	SD of mean	Mechanical (N=238)	Bioprosthetic (N=238)	p-value	SD of mean
Age (mean), years	67.4±4.6	67.6±4.3	0.57	4.5%	67.3±4.5	67.1±4.6	0.58	4.4%
Female, n (%)	101 (40.2%)	141 (45.5%)	0.21	10.7%	96 (40.3%)	85 (35.7%)	0.25	9.5%
Body mass index, kg/m ²	24.0±2.7	24.8±14.7	0.24	29.6%	24.1±2.8	24.4±3.0	0.34	10.3%
Body surface area, m ²	1.64±0.15	1.61±0.17	0.019	18.7%	1.65±0.15	1.67±0.14	0.11	13.8%
Smoking, n (%)	103 (41.0%)	106 (34.2%)	0.096	14.1%	99 (41.6%)	107 (45.0%)	0.40	6.9%
NYHA III/IV, n (%)	68 (27.1%)	91 (29.4%)	0.55	5.1%	67 (28.2%)	71 (29.8%)	0.68	3.5%
Hypertension, n (%)	103 (41.0%)	138 (44.5%)	0.41	7.1%	99 (41.6%)	100 (42.0%)	0.91	0.8%
Diabetes, n (%)	48 (19.1%)	70 (22.6%)	0.32	8.6%	44 (18.5%)	29 (12.2%)	0.06	17.5%
Previous MI, n (%)	3 (1.2%)	10 (3.2%)	0.11	13.7%	3 (1.3%)	2 (0.8%)	0.48	4.9%
Previous stroke, n (%)	9 (3.6%)	16 (5.2%)	0.37	7.8%	8 (3.4%)	12 (5.0%)	0.30	8.0%
Chronic AF, n (%)	20 (8.0%)	31 (10.0%)	0.41	7.0%	19 (8.0%)	14 (5.9%)	0.39	8.3%
Chronic renal failure, n (%)	6 (2.4%)	2 (0.6%)	0.15	14.8%	6 (2.5%)	2 (0.8%)	0.16	13.4%
Concurrent CABG, n (%)	53 (21.1%)	87 (28.1%)	0.054	16.3%	51 (21.4%)	42 (17.6%)	0.25	9.6%
Ejection fraction, %	53.2±12.2	51.1±13.6	0.08	16.3%	53.0±12.2	53.3±11.0	0.81	2.6%

AF: atrial fibrillation; CABG: coronary artery bypass graft; MI: myocardial infarction; NYHA: New York Heart Association functional class

160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212




Figure 1. Flow diagram detailing patient selection. AVR: aortic valve replacement; CABG: coronary artery bypass grafting

CLINICAL OUTCOMES

There were no differences in early outcomes between mechanical and bioprosthetic valves (Table 3). Four patients died after the index procedure in the mechanical group (1.6%), and eight patients died in the bioprosthetic group (2.6%, $p=0.42$).

In this registry, the 10-year cumulative mortality rate after AVR was 28.3% for patients who received mechanical valves and 31.6% for those who received bioprosthetic valves (unadjusted hazard ratio [HR] 1.30, 95% confidence interval [CI]: 0.91-1.86, $p=0.15$) (Figure 2A, Table 4). After risk adjustment, patients who received

Table 3. Early outcomes.

Variables	Mechanical (N=251)	Bioprosthetic (N=310)	<i>p</i> -value
Death, n (%)	4 (1.6)	8 (2.6)	0.42
Thromboembolism, n (%)	0 (0.0)	0 (0.0)	>0.99
Pacemaker insertion, n (%)	1 (0.4)	2 (0.6)	0.69
Wound infection, n (%)	1 (0.4)	3 (1.0)	0.63
Pneumonia, n (%)	0 (0.0)	1 (0.3)	>0.99
Low cardiac output syndrome, n (%)	3 (1.2)	1 (0.3)	0.33
Length of stay, days	10.5±7.1	10.7±7.2	0.85

Table 2. Operative characteristics.

Variables	Mechanical (N=251)	Bioprosthetic (N=310)	<i>p</i> -value
Type of valve disease			
Aortic stenosis, n (%)	105 (41.8%)	147 (47.4%)	
Aortic regurgitation, n (%)	59 (23.5%)	68 (21.9%)	0.47
Mixed aortic stenosis and regurgitation, n (%)	87 (34.7%)	95 (30.6%)	
Cardiopulmonary bypass time, min	129±62	123±51	0.28
Aorta cross clamp time, min	80±37	80±32	0.97
Mechanical valves			
Carbomedics		54 (21.5%)	
Edwards MIRA		15 (6.0%)	
St. Jude Medical		143 (57.0%)	
Sorin Bicarbon		26 (10.4%)	
Others		13 (5.2%)	
Bioprosthetic valves			
St. Jude Medical Biocor		31 (10.0%)	
Carpentier Edwards		197 (63.5%)	
Medtronic Hancock®		63 (20.3%)	
Others		19 (6.1%)	

bioprosthetic valves experienced a similar long-term survival rate to those who received mechanical valves (adjusted HR 1.25, 95% CI: 0.85-1.85, $p=0.26$) (Figure 2B, Table 5).

The 10-year cumulative reoperation rates were 1.3% for patients who received mechanical valves and 5.8% for those who received bioprosthetic valves (Table 4). The incidence of aortic valve reoperation was higher among patients who received bioprosthetic valves than among those who received mechanical valves although the difference did not reach statistical significance (unadjusted HR 2.70, 95% CI: 0.73-10.00; $p=0.14$). The result from the propensity score-matched cohort was similar (adjusted HR 2.94, 95% CI: 0.79-11.11, $p=0.11$) (Figure 3A, Table 5).

The 10-year incidence of bleeding events was 24.5% for patients given mechanical valves and 6.9% for those given bioprosthetic valves as shown in (unadjusted HR 0.30, 95% CI: 0.16-0.54, $p<0.0001$) (Table 4). After risk adjustment, patients who received bioprosthetic valves had a lower risk of bleeding (adjusted HR 0.25, 95% CI: 0.12-0.52, $p<0.0001$) (Figure 3B). Among bleeding events, cerebral haemorrhage was lower in patients who received bioprosthetic valves (unadjusted HR 0.12, 95% CI: 0.01-0.97, $p=0.046$), but this statistically significant difference diminished after risk adjustment (adjusted HR 0.15, 95% CI: 0.02-1.22, $p=0.08$). Among




Figure 2. Kaplan-Meier curves showing the unadjusted survival rate (A) and adjusted survival rate (B) according to valve type.

51 patients who experienced bleeding events, 30 patients required hospitalisation (mechanical valve, $n=22$; bioprosthetic valve, $n=8$). There was a significant difference in the cumulative incidence of subsequent hospitalisation between the two groups (14.4% vs. 4.5%, $p=0.009$). Overall in-hospital duration was 12.0 ± 19.7 days (mechanical valve, 14.2 ± 23.4 days; bioprosthetic valve, 7.1 ± 5.2 days, $p=0.35$). Among those who experienced bleeding events, 26 patients received a transfusion (mechanical valve, $n=21$; bioprosthetic valve, $n=5$). There was a significant difference in the cumulative incidence of receiving a transfusion (14.3% vs. 2.3%, $p<0.001$). There were no differences between the two groups in terms of units of transfused red blood cells, (3.3 ± 1.8 units vs. 4.3 ± 2.1 units, $p=0.47$), nor with fresh frozen plasma (3.5 ± 1.8 units vs. 4.0 ± 2.7 units, $p=0.67$). In line with total bleeding events, patients given a mechanical valve had a higher risk of hospitalisation due to a bleeding event (unadjusted HR 0.38, 95% CI: 0.18-0.81, $p=0.012$), as well as receiving a transfusion (unadjusted HR 0.23, 95% CI: 0.09-0.55, $p=0.001$).

The 10-year incidence of thromboembolism was similar between patients receiving mechanical and bioprosthetic valves

(5.1% versus 6.5%; unadjusted HR, 1.03; 95% CI, 0.45 to 2.38; $p=0.94$) (Table 4). There were no significant differences in the thromboembolism rate after risk adjustment (adjusted HR 0.38, 95% CI: 0.10-1.40, $p=0.15$) (Figure 3C). In contrast, patients with bioprosthetic valves showed a trend towards more frequent endocarditis compared to those with mechanical valves (unadjusted HR 4.14, 95% CI: 0.91-18.87, $p=0.067$). This trend became evident after risk adjustment (adjusted HR 7.65, 95% CI: 1.74-33.52, $p=0.007$) (Figure 3D).

By 12 years, MAPE had occurred in 29.6% of patients with mechanical valves and in 16.8% of patients with bioprosthetic valves (unadjusted HR 0.61, 95% CI: 0.40-0.92, $p=0.017$) (Figure 3E). After risk adjustment, patients who received bioprosthetic valves had a lower risk of MAPE (adjusted HR 0.61, 95% CI: 0.39-0.96, $p=0.033$) (Figure 3F).

SUBGROUP ANALYSIS OF LONG-TERM MORTALITY

Long-term mortality in the mechanical and bioprosthetic groups was compared by patient subgroup (Figure 4). The risk of mortality

Table 4. Long-term outcomes.

Outcome	Mechanical valve (N=251)		Bioprosthetic valve (N=310)		p -value*
	Number of events	Incidence rate	Number of events	Incidence rate	
Death	44	28.3	64	31.6	0.15
Reoperation	3	2.4	7	5.8	0.12
Bleeding	38	24.5	13	6.9	<0.0001
Cerebral haemorrhage	6	4.8	1	1.4	0.017
Thromboembolisation	6	5.1	9	6.5	0.94
Thrombosis	0	0	0	0	>0.99
Embolism	6	5.1	9	6.5	0.94
Endocarditis	2	2.0	8	3.6	0.047
MAPE	52	29.6	40	16.8	0.016

* p -value was estimated by log-rank test. MAPE: major adverse prosthesis-related events

266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318




Figure 3. Kaplan-Meier curves showing the unadjusted and adjusted rates of reoperation (A), bleeding (B), thromboembolism (C), and endocarditis (D), according to valve type. Unadjusted (E) and adjusted (F) MAPE rates. MAPE: major adverse prosthesis-related events (including reoperation, bleeding, thromboembolism or endocarditis)

varied across patient characteristics. In general, the long-term mortality of patients who received bioprosthetic valves was similar to that of those who received mechanical valves. However, the

long-term mortality of patients treated with bioprosthetic valves was higher in female and NYHA Class III/IV subgroups compared to those with mechanical valves.

Table 5. Adjusted hazard ratio between mechanical and bioprosthetic valve replacement.

	Unadjusted HR		Adjusted HR	
	HR (95% CI)	p-value	HR (95% CI)	p-value
Death	1.30 (0.91-1.86)	0.15	1.25 (0.85-1.85)	0.26
Reoperation	2.70 (0.72-10.00)	0.14	2.94 (0.79-11.11)	0.11
Bleeding	0.30 (0.16-0.54)	<0.0001	0.25 (0.12-0.52)	<0.0001
Cerebral haemorrhage	0.12 (0.01-0.97)	0.046	0.15 (0.02-1.22)	0.08
Thromboembolisation	1.03 (0.45-2.38)	0.94	0.38 (0.10-1.40)	0.15
Endocarditis	4.14 (0.9-18.87)	0.067	7.65 (1.74-33.52)	0.007
MAPE	0.61 (0.40-0.92)	0.017	0.61 (0.39-0.96)	0.033

MAPE: major adverse prosthesis-related events

Discussion

This observational study of 561 patients between 60 and 75 years of age who underwent AVR with mechanical valves and bioprosthetic valves demonstrates that: 1) overall mortality was similar for patients with mechanical and bioprosthetic valves; 2) bleeding events were more common in patients with mechanical valves but endocarditis was more frequent in those with bioprosthetic valves; 3) reoperation tended to occur more frequently in patients with bioprosthetic valves; and 4) overall composite events were more frequent in patients given mechanical valves.

In the Veterans Administration Study, patients who underwent AVR with mechanical valves had a significantly higher 15-year survival rate than those with bioprosthetic valves³. Brown et al, in a one-to-one study, matched patients aged 50 to 70 years undergoing

AVR and found a 10-year survival of 68% in the mechanical valve group and 50% in the bioprosthetic valve group¹¹. However, other studies demonstrated similar long-term survival. In the Edinburgh Heart Valve Trial, at 12 years there was a survival advantage in the mechanical valve group compared with the bioprosthetic valve group, but this advantage disappeared at 20 years⁴. Brennan et al compared outcomes of the Medicare-linked cohort study and found patients given a bioprosthesis had a similar adjusted risk for death². Lung and Bland in a meta-analysis with regression analyses did not find significant differences in the survival rate between mechanical and bioprosthetic valves after correcting for age¹². Our data was consistent with these previous studies. In the present study, 10-year mortality was 35.7% in patients with mechanical valves and 38.0% in those with bioprosthetic valves (p=0.15). Adjusted outcomes showed no difference in 10-year mortality between the two groups.

Previously, the advantages and disadvantages of mechanical or bioprosthetic valves have been well documented. The advantageous durability of mechanical valves is offset by the risk of thromboembolism and the need for long-term anticoagulation and its associated risk of bleeding. In contrast, bioprosthetic valves do not require long-term anticoagulation yet carry the risk of structural failure and reoperation. In our study, bleeding events were more common in patients with mechanical valves, but endocarditis was more frequent in those with bioprosthetic valves. Reoperation tended to occur more frequently in patients with bioprosthetic valves; however, thromboembolism did not show a difference between the two groups. Due to the large number of bleeding events, overall MAPE rates were higher for patients with mechanical valves. Although treating reoperation and bleeding events equally is controversial,




Figure 4. Comparison of long-term mortality in mechanical and bioprosthetic groups by patient subgroup. AF: atrial fibrillation; EF: ejection fraction; HR: hazard ratio

372 promising less invasive treatment for degenerated bioprostheses
 373 (“valve-in-valve” TAVR)^{5,6} would allow us to consider the com-
 374 posite MAPE as non-negligible. In addition, the superior durabil-
 375 ity of current bioprostheses favours the selection of a bioprosthetic
 376 valve¹³.

377 Bleeding, where the event rate ranges from 13.7% at 10 years to
 378 24.4% at 15 years, is the Achilles heel of the mechanical valve^{2,11}.
 379 In addition to the risk of bleeding, warfarin requires restrictions on
 380 food, alcohol and drugs, and lifelong coagulation monitoring. To
 381 overcome this complication of mechanical valves, new oral antico-
 382 agulation was applied in a randomised trial, but failed because of an
 383 excess of thromboembolic and bleeding events¹⁴. Thus, a quality of
 384 life study needs to be instigated on the choice of prosthesis.

385 There is a paucity of Asian data on the long-term outcomes of
 386 aortic valve replacement with mechanical and bioprosthetic valves.
 387 The risk of bleeding and thromboembolism has been shown to be
 388 different according to race, as was the chance of bioprosthetic valve
 389 degeneration. Therefore, our data will provide important infor-
 390 mation for the selection of prosthetic valves for AVR in an Asian
 391 population.

392 The physicians involved in the decision-making process should
 393 be very aware of patient outcomes with the use of different prosthe-
 394 ses. An increasing risk of major adverse effects and lifestyle altera-
 395 tion, i.e., lifelong anticoagulation with warfarin after mechanical
 396 valve replacement, improved durability of new technologies but
 397 still relatively higher risk of reoperation after bioprosthetic valve
 398 replacement, the potential option of minimally invasive procedures
 399 in case of reoperation and, finally, the individual patient’s prefer-
 400 ence, should be fully discussed with the patient.

401 Study limitations

402 Our study has several important limitations. First, it was a single-
 403 centre observational study and may be subject to selection bias
 404 and confounding by unmeasured severity of illness which may be
 405 correlated with the use of different valves. Second, the number of
 406 patients and follow-up time duration were limited, and it is likely
 407 that reoperation after bioprosthetic valve replacement will increase.
 408 Finally, we could not reliably ascertain other important endpoints,
 409 such as cardiovascular symptoms, functional status or decrements
 410 in quality of life associated with the use of anticoagulation therapy
 411 for mechanical valves and the monitoring of anticoagulant dosages.
 412 Despite these limitations, the current analysis demonstrates clear
 413 findings in agreement with reported data, and provides important
 414 information to guide valve type selection for older patients in cur-
 415 rent daily practice.

416 Conclusions

417 The following observations should be made: 1) overall mortality
 418 was similar for patients with mechanical and bioprosthetic valves;
 419 2) bleeding events were more common in patients with mechanical
 420 valves but endocarditis was more frequent in those with biopros-
 421 thetic valves; 3) overall composite events were more frequent in
 422 patients given mechanical valves.

Impact on daily practice

The trend in current practice seems to be more use of biopros-
 thetic AVR with the possibility to use TAVR if prosthetic valve
 stenosis or regurgitation occurs. Although this strategy needs
 further investigation, our study provides important information
 about the choice of prosthesis in older patients.

Funding

This study was supported by a grant from the CardioVascular
 Research Foundation, Seoul, Republic of Korea.

Conflict of interest statement

The authors have no conflicts of interest to declare.

References

1. Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP 3rd, Guyton RA, O’Gara PT, Ruiz CE, Skubas NJ, Sorajja P, Sundt TM 3rd, Thomas JD; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol*. 2014;63:e57-185.
2. Brennan JM, Edwards FH, Zhao Y, O’Brien S, Booth ME, Dokholyan RS, Douglas PS, Peterson ED; DEcIDE AVR (Developing Evidence to Inform Decisions about Effectiveness-Aortic Valve Replacement) Research Team. Long-term safety and effectiveness of mechanical versus biologic aortic valve prostheses in older patients: results from the Society of Thoracic Surgeons Adult Cardiac Surgery National Database. *Circulation*. 2013;127:1647-55.
3. Hammermeister K, Sethi GK, Henderson WG, Grover FL, Oprian C, Rahimtoola SH. Outcomes 15 years after valve replacement with a mechanical versus a bioprosthetic valve: final report of the Veterans Affairs randomized trial. *J Am Coll Cardiol*. 2000;36:1152-8.
4. Oxenham H, Bloomfield P, Wheatley DJ, Lee RJ, Cunningham J, Prescott RJ, Miller HC. Twenty year comparison of a Bjork-Shiley mechanical heart valve with porcine bioprostheses. *Heart*. 2003;89:715-21.
5. Dvir D, Webb J, Brecker S, Bleiziffer S, Hildick-Smith D, Colombo A, Descoutures F, Hengstenberg C, Moat NE, Bekeredjian R, Napodano M, Testa L, Lefevre T, Guetta V, Nissen H, Hernandez JM, Roy D, Teles RC, Segev A, Dumonteil N, Fiorina C, Gotzmann M, Tchetchet D, Abdel-Wahab M, De Marco F, Baumbach A, Laborde JC, Kornowski R. Transcatheter aortic valve replacement for degenerative bioprosthetic surgical valves: results from the global valve-in-valve registry. *Circulation*. 2012;126:2335-44.
6. Dvir D, Webb JG, Bleiziffer S, Pasic M, Waksman R, Kodali S, Barbanti M, Latib A, Schaefer U, Rodes-Cabau J, Treede H, Piazza N, Hildick-Smith D, Himbert D, Walther T,

425 Hengstenberg C, Nissen H, Bekeredjian R, Presbitero P,
 426 Ferrari E, Segev A, de Weger A, Windecker S, Moat NE,
 427 Napodano M, Wilbring M, Cerillo AG, Brecker S, Tchetché D,
 428 Lefevre T, De Marco F, Fiorina C, Petronio AS, Teles RC,
 429 Testa L, Laborde JC, Leon MB, Kornowski R; Valve-in-Valve
 430 International Data Registry Investigators. Transcatheter aortic
 431 valve implantation in failed bioprosthetic surgical valves. *JAMA*.
 432 2014;312:162-70.

433 7. Stassano P, Di Tommaso L, Monaco M, Iorio F, Pepino P,
 434 Spampinato N, Vosa C. Aortic valve replacement: a prospective
 435 randomized evaluation of mechanical versus biological valves in
 436 patients ages 55 to 70 years. *J Am Coll Cardiol*. 2009;54:1862-8.

437 8. Chiang YP, Chikwe J, Moskowitz AJ, Itagaki S, Adams DH,
 438 Egorova NN. Survival and long-term outcomes following biopro-
 439 sthetic vs mechanical aortic valve replacement in patients aged 50 to
 440 69 years. *JAMA*. 2014;312:1323-9.

441 9. Akins CW, Miller DC, Turina MI, Kouchoukos NT,
 442 Blackstone EH, Grunkemeier GL, Takkenberg JJ, David TE,
 443 Butchart EG, Adams DH, Shahian DM, Hagl S, Mayer JE,
 444 Lytle BW; Councils of the American Association for Thoracic
 445 Surgery; Society of Thoracic Surgeons; European Association
 446 for Cardio-Thoracic Surgery; Ad Hoc Liaison Committee for

Standardizing Definitions of Prosthetic Heart Valve Morbidity.
 Guidelines for reporting mortality and morbidity after cardiac valve
 interventions. *J Thorac Cardiovasc Surg*. 2008;135:732-8.

10. Rosenbaum PR. *Observational Studies*. 2nd edition. New
 York: Springer; 2002. p.1-17.

11. Brown ML, Schaff HV, Lahr BD, Mullany CJ, Sundt TM,
 Dearani JA, McGregor CG, Orszulak TA. Aortic valve replacement
 in patients aged 50 to 70 years: improved outcome with mechanical
 versus biologic prostheses. *J Thorac Cardiovasc Surg*. 2008;
 135:878-84; discussion 884.

12. Lund O, Bland M. Risk-corrected impact of mechanical ver-
 sus bioprosthetic valves on long-term mortality after aortic valve
 replacement. *J Thorac Cardiovasc Surg*. 2006;132:20-6.

13. David TE, Ivanov J, Armstrong S, Feindel CM, Cohen G.
 Late results of heart valve replacement with the Hancock II bio-
 prosthesis. *J Thorac Cardiovasc Surg*. 2001;121:268-77.

14. Eikelboom JW, Connolly SJ, Brueckmann M, Granger CB,
 Kappetein AP, Mack MJ, Blatchford J, Devenny K, Friedman J,
 Guiver K, Harper R, Khder Y, Lobmeyer MT, Maas H, Voigt JU,
 Simoons ML, Van de Werf F; RE-ALIGN Investigators.
 Dabigatran versus warfarin in patients with mechanical heart
 valves. *N Engl J Med*. 2013;369:1206-14.